Armilla, Granada, Spain

Publication History View all

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Forty four marine actinomycetes of the family Microccocaceae isolated from sponges collected primarily in Florida Keys (USA) were selected from our strain collection to be studied as new sources for the production of bioactive natural products. A 16S rRNA gene based phylogenetic analysis showed that the strains are members of the genera Kocuria and Micrococcus. To assess their biosynthetic potential, the strains were PCR screened for the presence of secondary metabolite genes encoding nonribosomal synthetase (NRPS) and polyketide synthases (PKS). A small extract collection of 528 crude extracts generated from nutritional microfermentation arrays was tested for the production of bioactive secondary metabolites against clinically relevant strains (Bacillus subtilis, methicillin-resistant Staphylococcus aureus (MRSA), Acinetobacter baumannii and Candida albicans). Three independent isolates were shown to produce a new anti-MRSA bioactive compound that was identified as kocurin, a new member of the thiazolyl peptide family of antibiotics emphasizing the role of this family as a prolific resource for novel drugs.
    Marine Drugs 04/2013; 11(4):1071-1086. DOI:10.3390/md11041071
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A new thiazolyl peptide, kocurin (1), was isolated from culture broths of a marine-derived Kocuria palustris. Its structural elucidation was accomplished using a combination of spectroscopic and chemical methods, including HRMS, extensive 1D and 2D NMR analysis, MS/MS fragmentation, and chemical degradation and Marfey's analysis of the resulting amino acid residues. The structure herein reported corrects that previously assigned to PM181104 (3). Kocurin displayed activity against methicillin-resistant Staphylococcus aureus (MRSA), with MIC values in the submicromolar range.
    Marine Drugs 02/2013; 11(2):387-98. DOI:10.3390/md11020387
  • [Show abstract] [Hide abstract]
    ABSTRACT: Microbial natural products have been for decades one of the most successful sources of drugs to treat infectious diseases. The high occurrence of resistances to all major classes of known antibiotics represents today a new challenge and new classes of antibacterial compounds are urgently needed to respond to this unmet clinical need. While natural products discovery programs have been gradually abandoned by big pharma, smaller biotechnology companies and other research organizations are taking the lead in the discovery of novel antibacterials. A survey of recent patents has shown that in spite of the efforts, few novel compounds are being developed that can overcome most of the emerging multi-resistant and pan-resistant pathogens. In order to respond to the current challenges of discovering novel antibiotics, new approaches are required to be developed to further exploit the microbial resources and their biosynthetic potential as an untapped source of novel metabolites. Strategies to mine microbial collections for orphan biosynthetic pathways and novel species thought to be uncultivable, are emerging as a need within antibacterial drug discovery programs, in combination with high throughput screening and chemical dereplication of novel compounds. Different innovative methods that are being developed to respond to the new challenges that are faced today by drug discovery programs will ensure the evolution of these strategies into a completely new framework that will address the renovated interest in the discovery of novel classes of antibiotics.
    Recent Patents on Anti-Infective Drug Discovery 08/2012; DOI:10.2174/157489112803521968


  • Address
    Avenida del Conocimiento, 3, 18016, Armilla, Granada, Spain
  • Head of Institution
    Olga Genilloud, PhD
  • Website
  • Phone
    +34 958 993 965
  • Fax
    +34 958 846 710
Information provided on this web page is aggregated encyclopedic and bibliographical information relating to the named institution. Information provided is not approved by the institution itself. The institution’s logo (and/or other graphical identification, such as a coat of arms) is used only to identify the institution in a nominal way. Under certain jurisdictions it may be property of the institution.

19 Members View all

View all

Top publications last week by downloads

Journal of Applied Microbiology 07/2008; 104(6):1644-58. DOI:10.1111/j.1365-2672.2008.03735.x
Journal of Natural Products 01/2014; 77(1). DOI:10.1021/np400740u

Top Collaborating Institutions


This map visualizes which other institutions researchers from Fundación MEDINA have collaborated with.

Rg score distribution

See how the RG Scores of researchers from Fundación MEDINA are distributed.